David Fuller and Eoin Treacy's Comment of the Day
Category - General

    CAR-T therapies a blue-sky scenario

    Thanks to a subscriber for this report from HSBC focusing on Novartis which may be of interest. Here is a section:

    Kymriah indicated for refractory ALL patients, but other indications are larger. Although Kymriah is only approved in the US to treat the small number of patients with refractory acute lymphoblastic leukaemia (ALL), additional indications such as Diffuse Large B-Cell Lymphoma (DLBCL) represent a significantly larger addressable patient population. Kymriah is the first Chimaeric Antigen Receptor T-cell (CAR-T)-based treatment approved globally. 

    Blue-sky scenario not that much of a stretch…Over 100,000 patients die from leukaemias, lymphomas and myelomas (haematological cancers) annually in the US and Europe. They are largely, by definition, refractory to available treatments. In due course, this patient group, or a proportion of it, could be addressed by CAR-T-based treatments. Further, CAR-T-based treatments could potentially be used earlier in the treatment of cancers and potentially in some solid tumours as well. Note that these figure do not include Japan, China, or elsewhere. 

    …25% of refractory blood cancers, 2.5% of other cancers.  In our blue-sky scenario for CAR-T treatments, an assumption that 25% of refractory blood cancers and 2.5% of other refractory cancers in the US and EU could be treated with CAR-T therapies in due course (although this would require sizeable manufacturing expansion by all CAR-T manufacturers) would yield peak sales of just under USD26bn. If Novartis garnered 50%, it would generate peak sales of just under USD13bn for Kymriah and other CAR-T therapies versus USD3.3bn that we currently forecast (27,000 patients treated versus 7,200 on our current forecast). In our view, this bluesky scenario is not an unrealistic possibility in terms of patient numbers.

    This section continues in the Subscriber's Area.

    Hurricane Irma set to squeeze a lot more than just Florida's oranges

    This article by Myra Saefong may be of interest to subscribers. Here is a section:

    Frozen concentrated orange juice for November delivery OJX7, +2.98% rose 5.3 cents, or 3.8%, to $1.461 a pound in Thursday dealings on the ICE Futures U.S. exchange. It’s up more than 9% so far this week and is poised for the highest settlement since mid-May.

    “The damage to the orange crop is twofold: both short term disruption but also, to the extent crops are completely destroyed, it could have a longer term effect since it takes a few years to grow an orange tree to production, thus limiting supply for a longer period,” said Alan Konn, partner and managing director of Price Asset Management.

    Cotton prices have also rallied. December cotton CTZ7, +0.23%  settled at nearly 75 cents a pound Tuesday, the highest since mid-June, though prices pulled back Wednesday and Thursday.

    Cotton markets are also nervous because Harvey did an as yet uncalculated amount of damage in Texas,” which is the country’s top grower of cotton, said Gilbertie. “And if Irma affects Georgia, the country’s number three producer of cotton, the U.S. cotton industry will be dealt an immensely damaging blow.”

    This section continues in the Subscriber's Area.

    3D Sensing

    Thanks to a subscriber for this report from Deutsche Bank focusing on the evolution of augmented reality technology in the upcoming suite of new mobile phones. Here is a section: 

    It is a reflection of Apple’s influence on the smartphone market that Apple’s competitors are already lining up copycats to ship in 2018 even before the market reception to Apple’s iPhone 8 has actually been seen. By introducing facial recognition on the iPhone 8 leveraging 3D sensing, Apple is adding extra cost, but it is also enabling bezel minimisation and the fingerprint module to be removed. With the bezel removed, the real estate for adding 3D sensing is extremely small, but it looks like they have achieved an industry first – getting structured light to miniaturise on a smartphone. This is no mean feat and reflects considerable efforts since Apple acquired Primesense in 2013.

    This section continues in the Subscriber's Area.

    Ray Dalio's TED Talk on Idea Meritocracy

    Thanks to a subscriber for this article from Marketfolly.com containing a link to Ray Dalio’s TED Talk. Here is a section:

    He notes, "In order to be an effective investor, one has to bet against the consensus and be right." 

    Dalio walks through the biggest mistake he ever made and how it made him ask himself in any future decisions: "How do I know I'm right?"  He gained humility.

    The Bridgewater founder also takes us inside a meeting at Bridgewater and shows how they collect data on each person's ideas and believability.  Dalio says they do this because people naively and arrogantly hold opinions in their mind that are wrong.  But if you zoom out and gain perspective, you can see things through everybody's eyes and view things collectively. 

    "Collective decision making is so much better than individual decision making if it's done well.  It's been the secret sauce behind our success."

    This section continues in the Subscriber's Area.

    How a Bird Charity's Battle Against a Wind Farm Backfired

    This article by Jess Shankleman for Bloomberg may be of interest to subscribers. Here is a section: 

    When plans for Neart na Gaoithe started being developed in 2008, Siemens AG’s 3.6 megawatt turbine was the most popular among developers. Now manufacturers are working on machines that could be four times bigger, helping companies like Dong Energy A/S build projects cheaply enough to make money at market prices. The collapse in oil prices has also helped lower offshore wind costs, by making the sea vessels needed to install projects cheaper to hire.

    This section continues in the Subscriber's Area.